Completed EARLY_PHASE1 INTERVENTIONAL NCT00456976

Efficacy of Selegiline in Negative Symptoms of Schizophrenia

Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia

Sponsor: Tabriz University

Conditions Schizophrenia

Interventions Selegiline

Updated 7 times since 2017 Last updated: Jul 22, 2008 Started: Apr 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Tabriz University and has accumulated 7 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed EARLY_PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tabriz University

Data source: Tabriz University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tabriz, Iran